Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase 3 Study of NI-071 vs US-licensed Remicade (infliximab) in Rheumatoid Arthritis
2016-001064-11Phase 3Completed
- Sponsor
- Nichi-Iko Pharmaceutical
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GS07 in rheumatoid arthritis (RA), sponsored by Nichi-Iko Pharmaceutical. Started Mar 2017; status: completed.
02
Drugs
GS07
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-001064-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001064-11.